Position in EXEL
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$809,892
+$171,475 QoQ
Shares Held
14,885
0.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#365
of 757 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NorthCoast Asset Management LLC holds $60,121,102 across 7 Biotechnology names. EXEL ranks #6 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
95,246 | $47,311,545 | |
| 2 | INCY |
Incyte Corp
|
37,421 | $4,242,044 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,735 | $3,576,001 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
33,137 | $1,896,099 | |
| 5 | DRTS |
Alpha Tau Medical Ltd.
|
135,017 | $1,698,513 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
14,885 | $809,892 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,950 | $587,008 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $809,892 | 14,885 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $638,417 | 14,885 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $652,409 | 14,885 | Shares | Sole | 2026-02-20 | |
| 2025-09-30 | $804,400 | 19,477 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $841,751 | 19,096 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $719,017 | 19,475 | Shares | Sole | 2025-05-19 | |
| 2024-12-31 | $641,557 | 19,266 | Shares | Sole | 2025-08-25 | |
| 2024-09-30 | $460,327 | 17,739 | Shares | Sole | 2024-11-15 | |
| No filing history on record for this holder in this stock. | ||||||